Alpha 1 Biomedicals, SciClone news

The companies settled their dispute over ALBM's Thymosin alpha 1 by granting SCLN virtual control over the product in return for up to $35 million in royalty payments

Read the full 280 word article

How to gain access

Continue reading with a
two-week free trial.